Xeris Biopharma Holdings Inc (NASDAQ:XERS) shares are trading higher by around 9% after the company revised its FY23 outlook.
The company raised the lower end of its revenue guidance, revising the range to $155 million-$165 million (vs. consensus of $158.2 million) from $145 million-$165 million.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased